marijuana stocks news

 


17-Nov-2015

Results of Operations and Financial Condition, Regulation FD Disclosure

Item 2.02 Results of Operations and Financial ConditionThe information provided below in “Item 7.01- Regulation FD Disclosure” of this Current Report on Form 8-K is incorporated by reference into this Item 2.02.

 

Item 7.01 Regulation FD DisclosureOn November 17, 2015, CannaVEST Corp. (the “Company”) announced the release of its Third Quarter 2015 earnings. A copy of the press release issued by the Company announcing the release of Third Quarter 2015 earnings is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information set forth under this Item 7.01, including Exhibit 99.1, is being furnished and, as a result, such information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such Section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

AbbVie Inc. (ABBV) Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients

AbbVie Seeks New Indication for IMBRUVICA® (ibrutinib) in Pediatric Patients with Chronic…

United Cannabis Corporation (CNAB) Receives Approval For Clinical Trials On Its Prana P1 THC Activated Capsules For Chronic Pain

United Cannabis Corporation Receives Approval For Clinical Trials On Its Prana P1…

$GWPH Marijuana A Promising Treatment

Marijuana A Promising Treatment, But Research And Development Still Limited While the…

Cara Therapeutics, Inc. (CARA) Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment

Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim…